HIND — Vyome Holdings, Inc.

Summary of ReShape Lifesciences Q3 2024 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Q3 2024 revenue reached $2.3 million, up 6% year-over-year and 17% sequentially from Q2 2024. However, revenue for the nine months ended September 30, 2024, decreased by 7% to $6.2 million compared to the same period in 2023.
• Gross Profit: Gross profit for Q3 2024 was $1.4 million (63% margin), slightly up from $1.3 million (60% margin) in Q3 2023. For the nine months, gross profit remained stable at $3.7 million, with a margin increase to 60% from 55%.
• Operating Costs: Operating expenses decreased by 41% for the first nine months of 2024 compared to the previous year, largely due to cost-cutting measures.
• Adjusted EBITDA: Non-GAAP adjusted EBITDA improved to a profit of $1.6 million in Q3 2024, compared to a loss of $2.9 million in Q3 2023. The nine-month adjusted EBITDA loss was reduced to $5.6 million from $12 million in the prior year.
• Cash Position: The company ended the quarter with net working capital of $1.3 million, including cash and cash equivalents of $800,000.

2. Strategic Updates and Business Highlights:

• Product Launch: The company is focused on the commercial launch of the redesigned Lap-Band 2.0 FLEX, which has received positive feedback from initial surgeon trials and recently gained approval from Health Canada.
• NIH Grant: ReShape received a $241,000 supplemental grant from NIH for studies on its Diabetes Bloc-Stim Neuromodulation device, bringing total NIH funding to $1.15 million.
• Merger with Vyome Therapeutics: A merger agreement with Vyome was announced, along with an asset sale to Biorad for $5.16 million. This is expected to enhance shareholder value and leverage synergies between the companies.

3. Forward Guidance and Outlook:

• Management expressed optimism about the future, particularly regarding the potential of the Vyome merger and the ongoing commercialization of the Lap-Band 2.0 FLEX. They anticipate that the obesity market will expand as societal perceptions shift and more individuals seek medical intervention for obesity.

4. Bad News, Challenges, or Points of Concern:

• Competitive Pressures: The company continues to face challenges from GLP-1 receptor agonists, which have impacted sales volumes and market dynamics for bariatric surgery options.
• Revenue Decline: Despite recent growth, the overall revenue for the first nine months of 2024 has contracted compared to the previous year, indicating ongoing market challenges.
• Market Adoption: There is a noted low adoption rate of GLP-1s among the clinically obese population, suggesting that the market for obesity treatments remains largely untapped.

5. Notable Q&A Insights:

• Market Dynamics: Paul Hickey acknowledged the impact of GLP-1s on bariatric surgeries but expressed confidence that as patients experience diminishing returns from these medications, interest in less invasive options like the Lap-Band will grow.
• Vyome's Pipeline: Krishna Gupta discussed Vyome's focus on treating rare unmet medical needs, including malignant fungating wounds, and indicated that more details about their product pipeline would be shared in an upcoming investor presentation.

Overall, while ReShape Lifesciences is navigating competitive pressures and revenue challenges, strategic initiatives such as the merger with Vyome and the launch of new products position the company for potential growth and shareholder value enhancement in the future.